Literature DB >> 7850014

Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter.

M F Wesche1, M M Tiel-v-Buul, N J Smits, W M Wiersinga.   

Abstract

A retrospective follow-up study of 131I treatment was performed in 10 females (median age 48 years, range 40-74 years) with non-toxic multinodular goiter. The median dose of 131I given was 20 mCi (range 14-65 mCi). Thyroid volume was measured by ultrasonography. The median follow-up period was 26 months (range 12-68 months). Nine patients had a reduction of goiter size: thyroid volume decreased from 88 +/- 14.9 ml (mean +/- SEM) to 49 +/- 10.9 ml 1 year after 131I treatment. The relative decrease of goiter size was 48% after 1 year (N = 9) and 59% after 2 years (N = 5). One patient did not respond and was referred for operation. Side effects were mild spontaneously resolving radiation thyroiditis in one patient and subclinical hypothroidism in four patients. In conclusion, 131I treatment of non-toxic goiter is an effective treatment at the expense of post-radiation (subclinical) hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850014     DOI: 10.1530/eje.0.1320086

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  4 in total

1.  Radioiodine treatment of non-toxic multinodular goitre: effects of combination with lithium.

Authors:  Guia Vannucchi; Arturo Chiti; Deborah Mannavola; Davide Dazzi; Marcello Rodari; Sara Tadayyon; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-04       Impact factor: 9.236

2.  Long-term outcome of low-activity radioiodine administration preceded by adjuvant recombinant human TSH pretreatment in elderly subjects with multinodular goiter.

Authors:  Massimo Giusti; Mauro Caputo; Iolanda Calamia; Mariaclaudia Bagnara; Enrica Ceresola; Mara Schiavo; Michele Mussap; Diego Ferone; Francesco Minuto; Marcello Bagnasco
Journal:  Thyroid Res       Date:  2009-06-30

Review 3.  An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter.

Authors:  Geraldo Medeiros-Neto; Suemi Marui; Meyer Knobel
Journal:  Endocrine       Date:  2008-05-20       Impact factor: 3.633

4.  Radioiodine treatment for non-toxic goitre.

Authors:  Ulla Feldt-Rasmussen
Journal:  F1000 Med Rep       Date:  2009-09-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.